Evidence map›Paper›PMID 32704405›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2020

Evaluation of non-small cell lung cancer by PET/CT with

Francisco Osvaldo García-Pérez, Sevastian Salvador Medina-Ornelas, Feliciano Barron-Barron, Oscar Arrieta-Rodriguez

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Recent Advances in Cancer Imaging withNuclear medicine and molecular imaging · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Francisco Osvaldo García-PérezDepartament of Nuclear Medicine and Molecular Imaging, Instituto Nacional de Cancerología (INCan) Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, C.P. 14080, Ciudad de México, México.
Sevastian Salvador Medina-OrnelasDepartament of Nuclear Medicine and Molecular Imaging, Instituto Nacional de Cancerología (INCan) Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, C.P. 14080, Ciudad de México, México.
Feliciano Barron-BarronFunctional Unit of Thoracic Oncology and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan) Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, C.P. 14080, Ciudad de México, México.
Oscar Arrieta-RodriguezFunctional Unit of Thoracic Oncology and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan) Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, C.P. 14080, Ciudad de México, México.
Instituto Nacional de Cancerología · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human copper transporter 1 (hCtr1) is the main transporter of copper which has been involved as an essential cofactor in biological processes and mechanisms of action for cisplatin and its analogues. Although expression of hCtr1 is present in all tissues that require copper, several studies have showed that levels of expression are highly variable between normal and neoplastic tissues. We evaluated the potential diagnostic of the

Indexed as

64CuCl2 PET/CThuman copper transporterNon-small cell lung cancerplatinum

Identifiers

PMID32704405
PMCPMC7364381
OpenAlexW3046095492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.